Anabolic Therapies in Osteoporosis and Bone Regeneration

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2018 Dec 28

PMID 30587780

Citations 54

Authors

Gabriele Russow

Denise Jahn

Jessika Appelt

Sven Mardian

Serafeim Tsitsilonis

Johannes Keller

Affiliations

Soon will be listed here.

Abstract

Osteoporosis represents the most common bone disease worldwide and results in a significantly increased fracture risk. Extrinsic and intrinsic factors implicated in the development of osteoporosis are also associated with delayed fracture healing and impaired bone regeneration. Based on a steadily increasing life expectancy in modern societies, the global implications of osteoporosis and impaired bone healing are substantial. Research in the last decades has revealed several molecular pathways that stimulate bone formation and could be targeted to treat both osteoporosis and impaired fracture healing. The identification and development of therapeutic approaches modulating bone formation, rather than bone resorption, fulfils an essential clinical need, as treatment options for reversing bone loss and promoting bone regeneration are limited. This review focuses on currently available and future approaches that may have the potential to achieve these aims.

Citing Articles

Palm Tocotrienol Activates the Wnt3a/β-Catenin Signaling Pathway, Protecting MC3T3-E1 Osteoblasts from Cellular Damage Caused by Dexamethasone and Promoting Bone Formation.

Abdullah Sani N, Kamaruddin N, Soelaiman I, Pang K, Chin K, Ramli E Biomedicines. 2025; 13(1).

PMID: 39857826 PMC: 11762645. DOI: 10.3390/biomedicines13010243.

Gastrointestinal health and serum proteins are associated with BMD in postmenopausal women: a cross-sectional study.

Wang H, Jiang Q, Yan J, Yang J, Sun J, Wang Y Nutr Metab (Lond). 2024; 21(1):86.

PMID: 39506776 PMC: 11539781. DOI: 10.1186/s12986-024-00865-1.

Foxk1 promotes bone formation through inducing aerobic glycolysis.

Liu C, Feng N, Wang Z, Zheng K, Xie Y, Wang H Cell Death Differ. 2024; 31(12):1650-1663.

PMID: 39232134 PMC: 11618307. DOI: 10.1038/s41418-024-01371-w.

Personalized Approaches to Spine Surgery.

Patel A, Dada A, Saggi S, Yamada H, Ambati V, Goldstein E Int J Spine Surg. 2024; .

PMID: 39191475 PMC: 11687043. DOI: 10.14444/8644.

Enhanced vascularization and osseointegration under osteoporotic conditions through functional peptide coating on implant surfaces.

Liu J, Zhao B, Shen X, Lu D, He W, Zan X Mater Today Bio. 2024; 27:101150.

PMID: 39104902 PMC: 11298615. DOI: 10.1016/j.mtbio.2024.101150.

References

Andreassen T, Ejersted C, Oxlund H . Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res. 1999; 14(6):960-8. DOI: 10.1359/jbmr.1999.14.6.960. View

Engstrand T, Daluiski A, Bahamonde M, Melhus H, Lyons K . Transient production of bone morphogenetic protein 2 by allogeneic transplanted transduced cells induces bone formation. Hum Gene Ther. 2000; 11(1):205-11. DOI: 10.1089/10430340050016274. View

Teitelbaum S . Bone resorption by osteoclasts. Science. 2000; 289(5484):1504-8. DOI: 10.1126/science.289.5484.1504. View

Bolon B, Carter C, Daris M, Morony S, Capparelli C, Hsieh A . Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. Mol Ther. 2001; 3(2):197-205. DOI: 10.1006/mthe.2001.0245. View

Baltzer A, Whalen J, Wooley P, Latterman C, Truchan L, Robbins P . Gene therapy for osteoporosis: evaluation in a murine ovariectomy model. Gene Ther. 2002; 8(23):1770-6. DOI: 10.1038/sj.gt.3301594. View

Swarthout J, DAlonzo R, Selvamurugan N, Partridge N . Parathyroid hormone-dependent signaling pathways regulating genes in bone cells. Gene. 2002; 282(1-2):1-17. DOI: 10.1016/s0378-1119(01)00798-3. View

Canalis E, Economides A, Gazzerro E . Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev. 2003; 24(2):218-35. DOI: 10.1210/er.2002-0023. View

Luk K, Chen Y, Cheung K, Kung H, Lu W, Leong J . Adeno-associated virus-mediated bone morphogenetic protein-4 gene therapy for in vivo bone formation. Biochem Biophys Res Commun. 2003; 308(3):636-45. DOI: 10.1016/s0006-291x(03)01429-3. View

Kostenuik P, Bolon B, Morony S, Daris M, Geng Z, Carter C . Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. Bone. 2004; 34(4):656-64. DOI: 10.1016/j.bone.2003.12.006. View

10.

Liu B, Tang J, Ji J, Gu J . The expression of functional human parathyroid hormone in a gene therapy model for osteoporosis. Cell Tissue Res. 2004; 317(1):57-63. DOI: 10.1007/s00441-004-0903-9. View

11.

Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J . Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280(20):19883-7. DOI: 10.1074/jbc.M413274200. View

12.

Keller H, Kneissel M . SOST is a target gene for PTH in bone. Bone. 2005; 37(2):148-58. DOI: 10.1016/j.bone.2005.03.018. View

13.

Bellido T, Ali A, Gubrij I, Plotkin L, Fu Q, OBrien C . Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005; 146(11):4577-83. DOI: 10.1210/en.2005-0239. View

14.

Ulrich-Vinther M, Schwarz E, Pedersen F, Soballe K, Andreassen T . Gene therapy with human osteoprotegerin decreases callus remodeling with limited effects on biomechanical properties. Bone. 2005; 37(6):751-8. DOI: 10.1016/j.bone.2005.07.021. View

15.

Kawai M, Bessho K, Maruyama H, Miyazaki J, Yamamoto T . Human BMP-2 gene transfer using transcutaneous in vivo electroporation induced both intramembranous and endochondral ossification. Anat Rec A Discov Mol Cell Evol Biol. 2005; 287(2):1264-71. DOI: 10.1002/ar.a.20245. View

16.

Yue B, Lu B, Dai K, Zhang X, Yu C, Lou J . BMP2 gene therapy on the repair of bone defects of aged rats. Calcif Tissue Int. 2005; 77(6):395-403. DOI: 10.1007/s00223-005-0180-y. View

17.

Tobimatsu T, Kaji H, Sowa H, Naito J, Canaff L, Hendy G . Parathyroid hormone increases beta-catenin levels through Smad3 in mouse osteoblastic cells. Endocrinology. 2006; 147(5):2583-90. DOI: 10.1210/en.2005-1627. View

18.

Krishnan V, Bryant H, MacDougald O . Regulation of bone mass by Wnt signaling. J Clin Invest. 2006; 116(5):1202-9. PMC: 1451219. DOI: 10.1172/JCI28551. View

19.

Pluhar G, Turner A, Pierce A, Toth C, Wheeler D . A comparison of two biomaterial carriers for osteogenic protein-1 (BMP-7) in an ovine critical defect model. J Bone Joint Surg Br. 2006; 88(7):960-6. DOI: 10.1302/0301-620X.88B7.17056. View

20.

Canalis E, Mazziotti G, Giustina A, Bilezikian J . Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007; 18(10):1319-28. DOI: 10.1007/s00198-007-0394-0. View